Update from the Centers for Disease Control and Prevention
Tuberculin Skin Test – Aplisol Shortage
The Centers for Disease Control and Prevention (CDC) is expecting a 3–10 month nationwide shortage of Aplisol. Aplisol is one of two purified-protein derivative (PPD) tuberculin antigens licensed for use in performing tuberculin skin test (TST). The manufacturer notified the CDC that the anticipated interruption of supply of Aplisol 5 mL (50 multidose vials) in June 2019, followed by an interruption of the supply of Aplisol 1 mL (10 multidose vials) in November 2019. This time frame is the manufacturer’s current estimate and is subject to change.
There are two FDA-approved PPD tuberculin antigen products available in the United States for use in performing TSTs: Tubersol (Sanofi-Pasteur) and Aplisol. In controlled studies, the concordance between the two products is high.
The Indiana State Department of Health, Division of Long Term Care guidance at this time is the substitution of Tubersol for Aplisol for TST. Additional guidance will be issued should the shortage affect both Tubersol and Aplisol.